timothy sykes logo
BIAF Stock Draws Traders As Nasdaq Compliance And VA Deal Align Thumbnail
G Google News

BIAF Stock Draws Traders As Nasdaq Compliance And VA Deal Align

ELLIS HOBBS•UPDATED SEP. 17, 2026, 9:19 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

bioAffinity Technologies Inc. stocks have been trading up by 33.27 percent on optimism surrounding its latest diagnostic technology developments.

Key Takeaways For BIAF Traders

  • bioAffinity Technologies signed a nationwide federal healthcare distribution agreement with AvMEDICAL for its CyPath Lung test, opening doors to VA and other federal healthcare systems through established government channels.
  • The company is pushing CyPath Lung beyond early detection into post-treatment surveillance for lung cancer survivors, targeting recurrence and new primary cancers alongside standard imaging.
  • Management will deliver a corporate update and host one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting CyPath Lung adoption and platform expansion.
  • bioAffinity Technologies has regained full Nasdaq compliance for BIAF and BIAFW, clearing the near-term delisting overhang while the team focuses on commercial execution.

Candlestick Chart

Live Update At 09:18:56 EDT: On Thursday, September 17, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 33.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

For active traders, BIAF is acting like a classic low-float biotech with a story, not a steady cash machine. The fundamentals confirm that. bioAffinity Technologies generated about $6.1M in revenue over the last period, but profitability metrics are deeply negative. EBITDA sits around -$3.3M for the recent quarter, and net income was roughly -$3.4M. That’s normal territory for an early-stage diagnostics name still scaling.

Gross margin near 52.6% shows CyPath Lung has room to throw off solid unit economics once volume builds. But the company is burning cash to get there. Operating cash flow for the quarter came in around -$3.2M, while free cash flow was about -$3.3M. The balance sheet shows roughly $2.4M in cash at period end, plus modest debt and a current ratio around 1.4, so BIAF is not drowning in leverage, but it does rely on equity raises to fund the ramp.

More Breaking News

On the chart, BIAF has traded like a rollercoaster. The stock ran from $4.56 on 2026/08/31 to a high spike over $20 on 2026/09/04 before fading back toward the mid-single digits, closing at $5.35 on 2026/09/16. Intraday 5‑minute data shows violent swings each morning, with BIAF bouncing from the mid‑$5s into the $7–$8 range, then back again. For day traders, that volatility and liquidity around news and conference catalysts are the real edge right now.

Why Traders Are Watching BIAF’s New Catalysts

BIAF is getting attention because the story is finally lining up with real commercial access. The nationwide federal distribution agreement with AvMEDICAL is a big deal for a small-cap diagnostics company. Instead of knocking on doors one hospital at a time, bioAffinity Technologies now plugs CyPath Lung into a government-focused sales force and IDIQ contracting structure. That means easier entry into VA hospitals and other federal systems, where purchasing is centralized and volume can scale quickly once a product gains traction.

For traders, that kind of channel expansion is exactly what can re-rate a micro-cap like BIAF. Volume won’t show up overnight, but the path is there. Combine that with the second leg of the story: CyPath Lung moving beyond early detection into post-treatment surveillance for lung cancer survivors. Surveillance is not a one-and-done test; it’s repeat use over years. If clinicians adopt CyPath Lung as a complement to imaging, every eligible survivor could translate into recurring test revenue, deepening BIAF’s revenue base.

The H.C. Wainwright conference on 2026/09/03 adds another catalyst. Corporate updates and one-on-one meetings often bring new eyes and higher trading volume into names like BIAF, especially when they already have volatile charts. Finally, the company’s regained Nasdaq compliance removes a major psychological overhang. Traders no longer have to price in imminent delisting risk, which can stabilize the bid and make it easier for momentum to hold when BIAF catches a run.

Conclusion

Putting it all together, BIAF is a textbook story stock for active traders to track. bioAffinity Technologies is not yet about clean profits or stable cash flows; it is about execution on a focused product, CyPath Lung, and a string of supportive catalysts. The AvMEDICAL deal opens the federal healthcare channel. The push into survivor surveillance adds a potential recurring use case. The H.C. Wainwright update boosts visibility. And restored Nasdaq compliance keeps BIAF in the main arena where traders like to play.

The financials show risk: heavy losses, negative cash flow, and reliance on the equity markets. But that’s exactly the backdrop where news flow can dominate price action. BIAF has already proven it can move from the $4s into the teens and beyond on momentum. Going forward, traders should study the intraday levels, watch for volume spikes around fresh commercialization updates, and be ready to cut losses quickly if the story stalls.

As Tim Sykes likes to say, “The market rewards prepared traders, not hopeful gamblers.” That mindset goes hand in hand with another of his core trading principles: As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.”. For BIAF, that means doing the homework on the CyPath Lung rollout, knowing the key dates, respecting the volatility, and treating every trade as an educational opportunity, not a guarantee. This analysis is for educational and research purposes only, but it shows why BIAF stays firmly on many watchlists.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”